Clinical trials: psoriasis
Psoriasis
Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis
This is a single-center, open-label, pilot study. A total of 30 subjects (15 in each study arm) will be enrolled in this 6 month study to evaluate whether the addition of narrow band UVB (NB-UVB) phototherapy can enhance the…
- Trial name
- NCT00800982
- Testing
- Narrow band (310-312 nm) ultraviolet light B phototherapy, etanercept
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Psoriasis
Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis
Safety and Efficacy of IDP-118 Lotion to Ultravate® Cream, in the Treatment of Plaque Psoriasis
- Trial name
- NCT02785172
- Testing
- IDP-118 Vehicle Lotion, IDP-118 Vehicle Cream, IDP-118 Lotion
- Where
- 14 sites in United States
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Psoriasis
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
The purpose of this study is to investigate the long-term safety and efficacy of risankizumab in the treatment of moderate to severe chronic plaque psoriasis.
- Trial name
- LIMMITLESS (NCT03047395)
- Testing
- risankizumab
- Where
- 233 sites in United States, Australia and 15 more
- Volunteers
- 2,170 people
- Sponsor
- AbbVie
Plaque Psoriasis, Psoriasis Vulgaris
Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab
The trial investigates the efficacy and safety of brodalumab against guselkumab in treatment for patients with moderate-to-severe plaque psoriasis who still have some remaining symptoms after ustekinumab treatment.
- Conditions
- Plaque Psoriasis, Psoriasis Vulgaris, Psoriasis
- Trial name
- COBRA (NCT04533737)
- Testing
- Brodalumab, Guselkumab
- Where
- 65 sites in Austria, Belgium and 10 more
- Volunteers
- 113 people
- Sponsor
- LEO Pharma
Moderate to Severe Plaque Psoriasis
Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis
This is a Phase 2b, randomized, multicenter, double-blind, placebo-controlled, multiple-dose study designed to evaluate the efficacy, safety, and tolerability of NDI-034858 in participants with moderate to severe plaque…
- Trial name
- NCT04999839
- Testing
- NDI-034858 study drug
- Where
- 69 sites in United States, Canada
- Volunteers
- 259 people
- Sponsor
- Takeda
Psoriasis, Plaque Psoriasis
Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)
This is a Phase 2, open label, maximal usage PK and safety study of ARQ-151 cream 0.3% in pediatric subjects (ages 2 to 5 years old) with plaque psoriasis:
- Trial name
- NCT04746911
- Testing
- ARQ-151 cream 0.3%
- Where
- 18 sites in United States, Canada and 1 more
- Volunteers
- 10 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Palmoplantar Pustulosis
An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis
The purpose of this study is to evaluate the efficacy and safety of guselkumab for the treatment of participants with palmoplantar pustulosis.
- Trial name
- NCT02641730
- Testing
- Guselkumab
- Where
- 32 sites in Japan
- Volunteers
- 159 people
- Sponsor
- Janssen Pharmaceutical K.K.
Psoriasis
Topical Scalp Psoriasis Study Evaluating Topicort Topical Spray
A single center, study of 20 subjects to assess 4 weeks of therapy with Topicort® twice daily BID and 12 weeks twice daily on 2 consecutive days to patients with scalp psoriasis
- Trial name
- NCT02985736
- Testing
- Topicort Topical Spray
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Psoriasis Treatment Center of Central New Jersey
Psoriasis
A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis
The purpose of this study is to evaluate the efficacy (good or bad effects) and safety of ustekinumab in the treatment of patients with moderate to severe psoriasis in China.
- Trial name
- NCT01008995
- Testing
- ustekinumab
- Where
- 9 sites in China
- Volunteers
- 322 people
- Sponsor
- Centocor, Inc.
Psoriasis
Assessment of Long-Term Infliximab for Psoriasis (P05319)
This is a prospective Phase 4, open-label, non-randomized, observational, multi-center study of infliximab in participants with plaque-type psoriasis to assess the clinical response in real-world practice of long-term maintenance…
- Trial name
- REALITY (NCT00779675)
- Testing
- Infliximab
- Volunteers
- 660 people
- Sponsor
- Merck Sharp & Dohme LLC
Psoriasis
A Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy
Oral therapies for psoriasis, including methotrexate and acitretin, are often less effective when used as monotherapy (without other oral medicines or creams) than are newer biologic injected drugs.
- Trial name
- NCT01761019
- Testing
- Taclonex Topical Suspension
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Pittsburgh
Psoriasis
BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a randomized double blind, double dummy, placebo controlled, parallel design study that is being performed to assess the safety and efficacy of BI 655066 (risankizumab).
- Trial name
- NCT03000075
- Testing
- risankizumab
- Volunteers
- 182 people
- Sponsor
- AbbVie
Plaque Psoriasis
A Study Comparing AIN457 to Placebo in Subjects With a Diagnosis of Moderate to Severe Stable Plaque Psoriasis
This is a two-arm, parallel group, double-blind, placebo-controlled proof-of-concept study comparing 3 mg/kg of AIN457 to placebo.
- Trial name
- NCT00669916
- Testing
- AIN457
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Scalp Psoriasis
Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis
The purpose of the study is to evaluate the safety and efficacy of once daily use of LEO 80185 topical suspension in adolescent subjects (aged 12 to 17 years) with scalp psoriasis.
- Trial name
- NCT01083758
- Testing
- LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel)
- Where
- 6 sites in United States
- Volunteers
- 31 people
- Sponsor
- LEO Pharma
Plaque Psoriasis
A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis
Study to evaluate pharmacokinetics, efficacy, safety and immunogenicity of multiple switches between Humira® and ABP 501 (new high concentration formulation) compared with continued use of Humira® in participants with moderate to…
- Trial name
- NCT05073315
- Testing
- Adalimumab, ABP 501
- Where
- 88 sites in United States, Canada and 4 more
- Volunteers
- 425 people
- Sponsor
- Amgen
Skin and Connective Tissue Diseases
A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris
The purpose of this study is to evaluate the anti-psoriatic effect of LEO 90100 aerosol foam compared with Betesil® medicated plaster
- Trial name
- NCT02518048
- Testing
- LEO 90100 Aerosol foam, Betesil® 2.25 mg
- Where
- France
- Volunteers
- 35 people
- Sponsor
- LEO Pharma
Psoriasis
A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to evaluate the efficacy and safety of initial single and multiple subcutaneous injections of CNTO 1275 in the treatment of patients with moderate to severe plaque psoriasis.
- Trial name
- NCT00320216
- Testing
- Ustekinumab
- Volunteers
- 320 people
- Sponsor
- Centocor, Inc.
Psoriasis Vulgaris
A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis
This is a vehicle and comparator controlled Proof of Mechanism (PoM) trial to evaluate the effect on psoriasis disease activity and safety of topically applied PF 06263276 in subjects with psoriasis vulgaris.
- Trial name
- NCT02193815
- Testing
- PF06263276, Vehicle, 2%Tofacitinib Ointment
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- Pfizer
Scalp Psoriasis
Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis
The purpose of the study is to evaluate the safety and efficacy of once daily use of LEO 80185 gel in adolescent subjects (aged 12 to 17) with scalp psoriasis.
- Trial name
- NCT01120223
- Testing
- LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)
- Where
- 17 sites in Canada, France and 1 more
- Volunteers
- 78 people
- Sponsor
- LEO Pharma
Psoriasis
Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis
The purpose of this study is to assess safety, and tolerability of multiple doses of ILV-094 administered to subjects with psoriasis
- Trial name
- NCT00563524
- Testing
- ILV-094
- Where
- 24 sites in United States, Canada and 2 more
- Volunteers
- 76 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer